Aurin Biotech is a pre-clinical stage company dedicated to the development of novel agents with the potential for breakthrough clinical applications. Our mission is to help to fill the enormous need for safe, effective, and orally available therapeutics capable of controlling abnormal activation of the body’s complement system.
The complement cascade is the backbone of our innate immune system; however, over activation or insufficient regulation of this powerful system is implicated in the pathologies of a wide variety of conditions. Read more
Self-attack by the body’s own complement system plays a role in a broad spectrum of human diseases. To date, researchers have implicated the system in over 30 illnesses. Read more
Our drug candidates reduce complement-mediated tissue damage by inhibiting key steps in the complement cascade. Our lead drug candidate is orally effective and holds promise to become one of the most wide spectrum therapeutic agents ever developed. Read more
Aurin Biotech Inc. is a private company established to advance the development of a remarkable collection of small molecules that can block self-attack due to pathological activation of the complement system. Read more
Aurin Biotech was founded to advance the breakthrough discoveries made by the McGeer and Associates Laboratory at the University of British Columbia (UBC). Read more
Aurin Biotech was founded by two of the world’s most cited neuroscientists and their hand-picked team. Our lean company is led by its founders and is supported by a talented Board and management team. Read more